Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RANGE: Treat and Extend Eylea for Wet AMD
NCT01961414Phase 4Unknown
- Sponsor
- Palmetto Retina Center
- Start
- Oct 2013
- Primary completion
- Mar 2016
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label trial of aflibercept in exudative age-related macular degeneration, sponsored by Palmetto Retina Center. Primary endpoint: Portion of patients who maintain vision (loss of <= 5 letters ETDRS BCVA) at 1 year. Status: unknown.
02
Drugs
aflibercept
03
Conditions
exudative age-related macular degeneration
Beyond the preview
Go deeper on NCT01961414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01961414.